Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

Inclusion Criteria * Patients entering the Phase 1 portion of the study must have a histologically or cytologically documented diagnosis of cancer (solid tumors) refractory to conventional therapeutic modalities or for which no conventional treatment exists. * Patients entering the Phase 2 portion of the study must have a histologically or cytologically documented diagnosis of advanced (Stage IIIb/IV) NSCLC. * Patients entering the Phase 1 portion of the study can have either measurable or evaluable disease. * Patients entering the Phase 2 portion of the study must have measurable disease meeting RECIST criteria. * Patients must have an ECOG performance status of less than or equal to 1. * More than 2 weeks must have elapsed since previous chemotherapy and 6 weeks from previous treatment with nitrosoureas or mitomycin-C. * Patients must have fully recovered from the toxic effects of prior therapy. * Patients entering the Phase 1 portion of the study may have received up to two prior chemotherapy programs including adjuvant or neoadjuvant therapy. * Patients entering the Phase 2 portion of the study may have received only one prior chemotherapy program including adjuvant or neoadjuvant therapy for NSCLC. * More than 2 weeks must have elapsed since previous radiation therapy and prior radiation must be less than or equal to 15% of the bone marrow. * Required Initial Laboratory Data: \*ANC ≥ 1,500/mm3, \*Platelet count ≥ 100,000/mm3, \*SGPT \< 1.5 times ULN, \*Alkaline phosphatase \< 2.0 times ULN, \*Bilirubin \< 1.5 mg/dl, \*Serum creatinine \< 1.5 times ULN Exclusion Criteria: * Pregnant or lactating women. * Uncontrolled high blood pressure, uncontrolled diabetes mellitus, unstable angina, symptomatic congestive heart failure (CHF), myocardial infarction (MI) within 6 months, or uncontrolled arrhythmia. * Phase 2 no previous or concurrent malignancy * Central Nervous System (CNS) metastasis if neurologically unstable or requiring steroid use. * Active infection. * Known positive HIV status. * Conditions requiring use of H2 blockers or other antacids. * Inability to provide informed consent.